Cobalt International Energy, Chelsea Therapeutics International, Kenneth Cole Productions - CRWESelect.com Stock News! (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) February 24, 2012 --



Cobalt International Energy, Inc. (NYSE:CIE)
Cobalt International Energy, Inc. ( CIE ) reported the pricing of a registered underwritten public offering of 52,000,000 shares of its common stock . Cobalt has agreed to sell 15,700,000 shares of its common stock and the selling stockholders have agreed to sell 36,300,000 shares of Cobalt’s common stock, each at a public offering price of $28.00 per share . Total aggregate gross proceeds to Cobalt and the selling stockholders is approximately $1.5 billion.

CIE intends to use the net proceeds from its sale of shares of common stock to fund its capital expenditures and for general corporate purposes.
CIE is an independent oil exploration and production company focusing on the deepwater U.S. Gulf of Mexico and offshore Angola and Gabon in West Africa. Cobalt was formed in 2005 and is headquartered in Houston, Texas.
For more information about CIE please visit http://www.cobaltintl.com
****
Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP)

Chelsea Therapeutics International, Ltd. ( CHTP ) recently reported that the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee voted 7-4 with 1 abstention and 1 non-vote to recommend approval of NORTHERA (TM) (droxidopa) for the treatment of symptomatic neurogenic ortho static hypotension in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

CHTP is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. CHTP 's most advanced drug candidate, NORTHERA(TM) (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to droxidopa, CHTP is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
For more information about CHTP please visit http://www.chelseatherapeutics.com
*****
Kenneth Cole Productions, Inc. (NYSE:KCP)
Fashion designer Kenneth Cole is offering to pay about $148.5 million to buy the rest of Kenneth Cole Productions, Inc. ( KCP ), saying it would compete more effectively as a privately-held company.
KCP designs, sources, and markets a range of fashion footwear, handbags, and apparel in the United States and internationally.
For more information about KCP please visit http://www.kennethcole.com

To read the full article visit URL http://crweselect.com/28746/stock-alerts/cie-chtp-kcp-crweselectcom-stock-news-cobalt-international-energy-chelsea-therapeutics-international-kenneth-cole-productions-video-included-inside/


THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer : Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://crweselect.com/disclaimer / ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
CIEcrweselect0224
CHTPcrweselect0224
KCPcrweselect0224